Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily

Journal of Clinical Oncology

Volumn 20, Issue 18, 2002, Pages 3772-3784

  Eder Jr , Joseph P ^a   Supko, Jeffrey G ^a   Clark, Jeffrey W ^a   Puchalski, Thomas A ^a   Garcia Carbonero, Rocio ^a   Ryan, David P ^a   Shulman, Lawrence N ^a   Proper, Joann ^a   Kirvan, Moira ^a   Rattner, Barbara ^a   Connors, Susan ^a   Keogan, Mary T ^a   Janicek, Milos J ^a   Fogler, William E ^a   Schnipper, Lowell ^a   Kinchla, Nancy ^a   Sidor, Carolyn ^a   Phillips, Eric ^a   Folkman, Judah ^a   Kufe, Donald W ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIBODY; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; HEPARIN; VASCULOTROPIN; WARFARIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SOLID TUMOR; TREATMENT OUTCOME; TUMOR BLOOD FLOW;

ADULT; AGED; ANGIOGENESIS INHIBITORS; COLLAGEN; CREATININE; ENDOSTATINS; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOKINES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASMS; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; TIME FACTORS; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037106508     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.02.082     Document Type: Article

References (56)

1. Tumor angiogenesis: Therapeutic implications
2. Angiogenic factors
3. Control of angiogenesis with synthetic heparin substitutes
4. Clinical implications of circulating angiogenic factors in cancer patients
5. Angiogenic balance in human melanoma: Expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo
6. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
7. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
8. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis
9. Mouse Colla1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones
10. Collagen XVIII is a basement membrane heparan sulfate proteoglycan
11. Mouse endostatin inhibits the formation of lung and liver metastases
12. Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth
13. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metallopreteinase
14. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
15. Zinc ligand-disrupted recombinant human endostatin: Potent inhibitions of tumor growth, safety and pharmacokinetic profile
16. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
17. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging
18. Fast dynamic contrast-enhanced colour-coded MRI in uterine cervix carcinoma: Usefulness for tumour staging
19. Endothelial cell proliferation activity in benign prostatic hyperplasia and prostate cancer: An in vitro model for assessment
20. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?
21. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer
22. Optimality assessment in the enzyme-linked immunosorbent assay (ELISA)
23. Preparation of mean drug concentrationtime curves in plasma: A study on the frequency distribution of pharmacokinetic parameters
24. Common noncompartmental pharmacokinetic variables: Are they normally or log-normally distributed?
25. Estimation of variance for harmonic mean half-lives
26. Compartmental pharmacokinetics and tissue drug distribution of the pradimicin derivative BMS 181184 in rabbits
27. Comparison of methods for estimating individual pharmacokinetic parameters
28. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a
29. Antiangiogenic strategies and agents in clinical trials
30. Angiostatin and endostatin: Endogenous inhibitors of tumor growth
31. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution
32. Variable zinc coordination in endostatin
33. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics
34. In vivo monitoring of tumor angiogenesis with MR imaging
35. Pharmacokinetic analysis of neoplasms using contrast-enhanced dynamic magnetic resonance imaging
36. Key factors in the acquisition of contrast kinetic data for oncology
37. Uterine cervical carcinoma: Comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival
38. Assessment of tumor microcirculation: A new role of dynamic contrast MR imaging
39. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a
40. Cellular markers that distinguish the phases of hemangioma during infancy and childhood
41. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis
42. Serum endostatin levels in patients with hepatocellular carcinoma
43. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma
44. Circulating levels of endostatin in cancer patients
45. Clinical pharmacokinetics of interferons
46. Pharmacokinetics of recombinant human interleukin-11 (rhIL-11) in healthy male subjects
47. Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative
48. Body surface area as a determinant of pharmacokinetics and drug dosing
49. Cloning, expression, and in vitro activity of human endostatin
50. Efficacy of the angiogenesis inhibitor (chloroacetyl-carbamoyl)fumagillol (AGM-1470) on osteosarcoma growth and lung metastases in rats
51. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy
52. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model